Related Experiment Video
Updated: Jun 13, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention
G Aurilio1, D Serrano1, M Lazzeroni1
1Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, Milan, Italy.
Abstract:
Window-of-opportunity trials are a path to screen effective agents and optimize dose in breast cancer risk reduction. We review the scientific evidence regarding the utility of window-of-opportunity trials to screen effective agents and optimize dose for successful risk reduction/interception of breast cancer. Low-dose tamoxifen was evaluated in a window-of-opportunity trial and then validated in a phase-III trial. We are now studying similar activity with low-dose exemestane.
Insights
Window-of-opportunity trials effectively screen breast cancer risk reduction agents. Low-dose tamoxifen showed success, and similar studies are underway with low-dose exemestane for breast cancer interception.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacology
Background:
- Window-of-opportunity trials are crucial for evaluating breast cancer risk reduction strategies.
- Identifying effective agents and optimal dosing is key for successful cancer interception.
Purpose of the Study:
- To review the scientific evidence supporting window-of-opportunity trials in breast cancer risk reduction.
- To assess the utility of these trials in screening agents and optimizing dose.
Main Methods:
- Review of scientific literature on window-of-opportunity trials for breast cancer.
- Analysis of past trials, including low-dose tamoxifen and ongoing exemestane studies.
Main Results:
- Low-dose tamoxifen was successfully evaluated in a window-of-opportunity trial.
- This agent was subsequently validated in a phase-III trial for breast cancer risk reduction.
Conclusions:
- Window-of-opportunity trials are a valuable tool for breast cancer risk reduction research.
- Further investigation into agents like low-dose exemestane is warranted for cancer interception.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
Clinical Trials: Overview
Drug Discovery: Overview
Cancer Survival Analysis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hazard Ratio
For example, in a clinical trial...
Clinical Trials
There are four phases in a clinical trial. A phase one...